114 related articles for article (PubMed ID: 34653281)
1. Besifovir therapy improves hepatic histology and reduces covalently closed circular DNA in chronic hepatitis B patients.
Yim HJ; Kim W; Ahn SH; Jung YK; Um SH; Sohn JH; Jang JY; Kim DJ; Park ES; Jin SY; Kim KH
J Gastroenterol Hepatol; 2022 Feb; 37(2):378-386. PubMed ID: 34653281
[TBL] [Abstract][Full Text] [Related]
2. Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial.
Song DS; Kim W; Ahn SH; Yim HJ; Jang JY; Kweon YO; Cho YK; Kim YJ; Hong GY; Kim DJ; Jung YK; Sohn JH; Lee JW; Park SJ; Lee BS; Kim JH; Kim HS; Yoon SK; Kim MY; Lee KS; Lim YS; Lee WS; Yang JM; Kim KH; Han KH; Um SH
Clin Mol Hepatol; 2021 Apr; 27(2):346-359. PubMed ID: 33493393
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Besifovir Dipivoxil Maleate Compared With Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection.
Ahn SH; Kim W; Jung YK; Yang JM; Jang JY; Kweon YO; Cho YK; Kim YJ; Hong GY; Kim DJ; Um SH; Sohn JH; Lee JW; Park SJ; Lee BS; Kim JH; Kim HS; Yoon SK; Kim MY; Yim HJ; Lee KS; Lim YS; Lee WS; Park NH; Jin SY; Kim KH; Choi W; Han KH
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1850-1859.e4. PubMed ID: 30448598
[TBL] [Abstract][Full Text] [Related]
4. Besifovir Dipivoxil Maleate 144-Week Treatment of Chronic Hepatitis B: An Open-Label Extensional Study of a Phase 3 Trial.
Yim HJ; Kim W; Ahn SH; Yang JM; Jang JY; Kweon YO; Cho YK; Kim YJ; Hong GY; Kim DJ; Jung YK; Um SH; Sohn JH; Lee JW; Park SJ; Lee BS; Kim JH; Kim HS; Yoon SK; Kim MY; Lee KS; Lim YS; Lee WS; Han KH
Am J Gastroenterol; 2020 Aug; 115(8):1217-1225. PubMed ID: 32355123
[TBL] [Abstract][Full Text] [Related]
5. Influence of Besifovir Dipivoxil Maleate Combined with L-Carnitine on Hepatic Steatosis in Patients with Chronic Hepatitis B.
Jung YW; Kim M; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Kim SU
J Korean Med Sci; 2020 May; 35(17):e104. PubMed ID: 32356416
[TBL] [Abstract][Full Text] [Related]
6. Association of intrahepatic cccDNA reduction with the improvement of liver histology in chronic hepatitis B patients receiving oral antiviral agents.
Cheng PN; Liu WC; Tsai HW; Wu IC; Chang TT; Young KC
J Med Virol; 2011 Apr; 83(4):602-7. PubMed ID: 21328373
[TBL] [Abstract][Full Text] [Related]
7. Similar risk of kidney function decline between tenofovir alafenamide and besifovir dipivoxil maleate in chronic hepatitis B.
Jung CY; Kim HW; Lee JI; Lee HW; Ahn SH; Kim SU; Kim BS
Liver Int; 2022 Nov; 42(11):2408-2417. PubMed ID: 35943853
[TBL] [Abstract][Full Text] [Related]
8. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine.
Bowden S; Locarnini S; Chang TT; Chao YC; Han KH; Gish RG; de Man RA; Yu M; Llamoso C; Tang H
World J Gastroenterol; 2015 Apr; 21(15):4644-51. PubMed ID: 25914474
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
[TBL] [Abstract][Full Text] [Related]
10. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients.
Testoni B; Lebossé F; Scholtes C; Berby F; Miaglia C; Subic M; Loglio A; Facchetti F; Lampertico P; Levrero M; Zoulim F
J Hepatol; 2019 Apr; 70(4):615-625. PubMed ID: 30529504
[TBL] [Abstract][Full Text] [Related]
11. Correlation of HBcrAg with Intrahepatic Hepatitis B Virus Total DNA and Covalently Closed Circular DNA in HBeAg-Positive Chronic Hepatitis B Patients.
Wang L; Cao X; Wang Z; Gao Y; Deng J; Liu X; Zhuang H
J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30355757
[TBL] [Abstract][Full Text] [Related]
12. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
Yang DH; Xie YJ; Zhao NF; Pan HY; Li MW; Huang HJ
World J Gastroenterol; 2015 Mar; 21(9):2746-53. PubMed ID: 25759545
[TBL] [Abstract][Full Text] [Related]
13. Besifovir dipivoxil maleate: a novel antiviral agent with low toxicity and high genetic barriers for chronic hepatitis B.
Song JE; Park JY
Expert Opin Pharmacother; 2021 Dec; 22(18):2427-2433. PubMed ID: 34392744
[TBL] [Abstract][Full Text] [Related]
14. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
[TBL] [Abstract][Full Text] [Related]
15. Impact of peginterferon alpha-2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B.
Hagiwara S; Kudo M; Osaki Y; Matsuo H; Inuzuka T; Matsumoto A; Tanaka E; Sakurai T; Ueshima K; Inoue T; Yada N; Nishida N
J Med Virol; 2013 Jun; 85(6):987-95. PubMed ID: 23588724
[TBL] [Abstract][Full Text] [Related]
16. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B.
Wursthorn K; Lutgehetmann M; Dandri M; Volz T; Buggisch P; Zollner B; Longerich T; Schirmacher P; Metzler F; Zankel M; Fischer C; Currie G; Brosgart C; Petersen J
Hepatology; 2006 Sep; 44(3):675-84. PubMed ID: 16941693
[TBL] [Abstract][Full Text] [Related]
17. Tenofovir monotherapy versus tenofovir plus entecavir combination therapy in HBeAg-positive chronic hepatitis patients with partial virological response to entecavir.
Wang YH; Liao J; Zhang DM; Wu DB; Tao YC; Wang ML; Chen EQ; Tang H
J Med Virol; 2020 Mar; 92(3):302-308. PubMed ID: 31609007
[TBL] [Abstract][Full Text] [Related]
18. High efficacy of adefovir and entecavir combination therapy in patients with nucleoside-refractory hepatitis B.
Chae HB; Kim MJ; Seo EG; Choi YH; Lee HS; Han JH; Yoon SM; Park SM; Youn SJ
Korean J Hepatol; 2012 Mar; 18(1):75-83. PubMed ID: 22511906
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of intrahepatic hepatitis B virus covalently closed circular DNA and total DNA in patients with acute hepatitis B and patients with chronic hepatitis B receiving anti‑viral treatment.
Ruan P; Zhou B; Dai X; Sun Z; Guo X; Huang J; Gong Z
Mol Med Rep; 2014 Apr; 9(4):1135-41. PubMed ID: 24566465
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of addition of Tenofovir Disoproxil Fumarate to Peg-IFNα-2b is superior to the addition of Entecavir in HBeAg positive CHB patients with a poor response after 12 weeks of Peg-IFNα-2b treatment alone.
Lin S; Fu Y; Wu W; Chen T; Chen N; Xun Z; Liu C; Ou Q; Zeng Y; Huang H
Int J Med Sci; 2020; 17(10):1458-1463. PubMed ID: 32624702
[No Abstract] [Full Text] [Related]
[Next] [New Search]
